Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Total Liabilities (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Total Liabilities for 8 consecutive years, with $76.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 13.03% to $76.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $76.9 million, a 13.03% decrease, with the full-year FY2024 number at $80.0 million, down 43.23% from a year prior.
  • Total Liabilities was $76.9 million for Q3 2025 at Precision Biosciences, up from $74.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $203.5 million in Q1 2021 to a low of $74.9 million in Q2 2025.
  • A 5-year average of $130.1 million and a median of $129.6 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 105.2% in 2021, then tumbled 49.11% in 2025.
  • Precision Biosciences' Total Liabilities stood at $120.3 million in 2021, then surged by 47.71% to $177.7 million in 2022, then decreased by 20.71% to $140.9 million in 2023, then tumbled by 43.23% to $80.0 million in 2024, then fell by 3.9% to $76.9 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Total Liabilities are $76.9 million (Q3 2025), $74.9 million (Q2 2025), and $75.1 million (Q1 2025).